(S)-duloxetine (Q411932)

duloxetine (English)

18 November 2016

1 reference

C₁₈H₁₉NOS

1 reference

duloxetine (English)

18 November 2016

CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32

1 reference

duloxetine (English)

18 November 2016

CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32

1 reference

duloxetine (English)

18 November 2016

60 milligram

route of administration

oral administration

1 reference

https://www.whocc.no/atc_ddd_index/?code=N06AX21

active ingredient in

Ariclaim

1 reference

EMEA/H/C/000552

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000552/human_med_000654.jsp

22 March 2017

1 reference

14 February 2018

Duloxetine Boehringer Ingelheim

1 reference

EMEA/H/C/001007

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001007/human_med_000746.jsp

22 March 2017

Duloxetine Lilly

1 reference

EMEA/H/C/004000

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004000/human_med_001828.jsp

22 March 2017

Duloxetine Mylan

1 reference

EMEA/H/C/003981

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003981/human_med_001871.jsp

22 March 2017

Duloxetine Zentiva

1 reference

EMEA/H/C/003935

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003935/human_med_001894.jsp

22 March 2017

Xeristar

1 reference

EMEA/H/C/000573

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000573/human_med_001159.jsp

22 March 2017

1 reference

14 February 2018

World Health Organisation international non-proprietary name

duloxetine (English)

1 reference

Duloxetine (English)

medical condition treated

19 January 2016

generalized anxiety disorder

1 reference

osteoarthritis susceptibility 1

2 October 2018

1 reference

2 October 2018

mood disorder

1 reference

2 October 2018

migraine

1 reference

2 October 2018

fibromyalgia

1 reference

2 October 2018

postpartum depression

1 reference

2 October 2018

mental disorder

1 reference

2 October 2018

arthritis

1 reference

obsessive-compulsive disorder

2 October 2018

1 reference

post-traumatic stress disorder

2 October 2018

1 reference

complex regional pain syndrome

2 October 2018

1 reference

2 October 2018

anxiety

1 reference

2 October 2018

peripheral neuropathy

1 reference

2 October 2018

anxiety disorder

1 reference

generalized anxiety disorder

2 October 2018

start time

2 August 2004

approved by

Food and Drug Administration

1 reference

Inxight: Drugs Database

2 November 2018

https://drugs.ncats.io/drug/O5TNM5N07U

http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021427s048lbl.pdf

major depressive disorder

start time

2 August 2004

approved by

Food and Drug Administration

1 reference

Inxight: Drugs Database

2 November 2018

https://drugs.ncats.io/drug/O5TNM5N07U

http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021427s048lbl.pdf

significant drug interaction

isocarboxazid

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

procarbazine

1 reference

High-priority drug–drug interactions for use in electronic health records

(±)-deprenyl

1 reference

High-priority drug–drug interactions for use in electronic health records

tranylcypromine

1 reference

High-priority drug–drug interactions for use in electronic health records

aspirin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

nabumetone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

naproxen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

celecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

Diclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

piroxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

meloxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-fenoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(+-)-flurbiprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ibuprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

indomethacin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-ketoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-etodolac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sulindac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clopidogrel

1 reference

A reference set of clinically relevant adverse drug-drug interactions

eptifibatide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

iloprost

1 reference

A reference set of clinically relevant adverse drug-drug interactions

prostacyclin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

parecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tirofiban

1 reference

A reference set of clinically relevant adverse drug-drug interactions

aceclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tenoxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

abciximab

1 reference

A reference set of clinically relevant adverse drug-drug interactions

rivaroxaban

1 reference

A reference set of clinically relevant adverse drug-drug interactions

apixaban

1 reference

A reference set of clinically relevant adverse drug-drug interactions

rac-warfarin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

acenocoumarol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

phenindione

1 reference

A reference set of clinically relevant adverse drug-drug interactions

paroxetine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sertraline

1 reference

A reference set of clinically relevant adverse drug-drug interactions

venlafaxine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fluvoxamine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fluoxetine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-citalopram

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

nabumetone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

naproxen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

celecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

Diclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

piroxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

meloxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-fenoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(+-)-flurbiprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ibuprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

indomethacin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-ketoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-etodolac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sulindac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

parecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

aceclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tenoxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

paroxetine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sertraline

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fluvoxamine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fluoxetine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-citalopram

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

geniospasm

1 reference

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

A reference set of clinically relevant adverse drug-drug interactions

hyperthermia

1 reference

A reference set of clinically relevant adverse drug-drug interactions

hypertension

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

bupropion

seizure

1 reference

A reference set of clinically relevant adverse drug-drug interactions

toxic encephalopathy

1 reference

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

A reference set of clinically relevant adverse drug-drug interactions

geniospasm

1 reference

A reference set of clinically relevant adverse drug-drug interactions

hyperthermia

1 reference

A reference set of clinically relevant adverse drug-drug interactions

hypertension

1 reference

A reference set of clinically relevant adverse drug-drug interactions

physically interacts with

5-hydroxytryptamine receptor 2A

1 reference

5-hydroxytryptamine receptor 2C

17 August 2016

1 reference

5-hydroxytryptamine receptor 6

17 August 2016

1 reference

Solute carrier family 6 member 2

17 August 2016

1 reference

solute carrier family 6 member 4

17 August 2016

1 reference

17 August 2016

legal status (medicine)

boxed warning

1 reference

https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/343802

Australian pregnancy category B3

FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links. (English)

pregnancy category

1 reference

imported from Wikimedia project

English Wikipedia

US pregnancy category C

1 reference

imported from Wikimedia project

English Wikipedia

LiverTox likelihood score

LiverTox toxicity likelihood category B

1 reference

8 April 2021

https://www.ncbi.nlm.nih.gov/books/n/livertox/Duloxetine

last update

8 January 2018

selective serotonin reuptake inhibitor

1 reference

5 March 2018

adrenergic uptake inhibitors

1 reference

5 March 2018

serotonin–norepinephrine reuptake inhibitor

0 references

DULoxetine

Institute for Safe Medication Practices

1 reference

https://www.ismp.org/recommendations/tall-man-letters-list

imported from Wikimedia project

2 September 2022

different from

dapoxetine

1 reference

English Wikipedia

Wikimedia import URL

https://en.wikipedia.org/w/index.php?title=Duloxetine&oldid=950468053

Commons category

Duloxetine

0 references

Identifiers

InChI

InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1

1 reference

duloxetine (English)

18 November 2016

2 references

duloxetine (English)

18 November 2016

ChEBI release 2020-09-01

CAS Registry Number

116539-59-4

2 references

duloxetine (English)

18 November 2016

https://commonchemistry.cas.org/detail?cas_rn=116539-59-4

10 April 2021

1 reference

Duloxetine (English)

18 November 2016

2 references

duloxetine (English)

18 November 2016

Reaxys registry number

4297128

1 reference

(S)-duloxetine (English)

19 October 2016

ChEBI ID

36795

mapping relation type

2 references

DULOXETINE (English)

18 November 2016

International Chemical Identifier

InChI

InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1

1 reference

DULOXETINE (English)

18 November 2016

2 references

inferred from InChIKey

splash10-0002-0590000000-894e0be7451e63140e89

1 reference

MassBank accession ID

SM850903

0 references

SPLASH

0 references

HSDB ID

7368

1 reference

Hazardous Substances Data Bank

28 October 2019

DULOXETINE (English)

10 May 2021

2 references

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

DSSTOX compound identifier

0 references

0 references

0 references

ECHA Substance Infocard ID

100.116.825

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.116.825

27 December 2018

N-Methyl-gama-(1-naphthalenyloxy)-2-thiophenepropanamine (English)

quotation

CAS no.: 116539-59-4 (English)

1 reference

Duloxetine (English)

publication date

17 November 2015

1 reference

duloxetine (English)

18 November 2016

0 references

1 reference

duloxetine (English)

18 November 2016

1 reference

Human Metabolome Database ID

HMDB0014619

2 references

based on heuristic

inferred from InChIKey

2 references

duloxetine (English)

18 November 2016

MedlinePlus drug identifier

a604030

0 references

PatientsLikeMe treatment ID

0 references

1 reference

duloxetine (English)

18 November 2016

0 references

1 reference

1 reference

https://docs.openalex.org/download-snapshot/snapshot-data-format

Duloxetine (English)

19 January 2016

0 references

1 reference

28 October 2013

Microsoft Academic ID

0 references

1 reference

26 January 2022

1 reference

26 January 2022

https://docs.openalex.org/download-snapshot/snapshot-data-format

1 reference

4MMD (English)

19 October 2016

1 reference

4MM6 (English)

19 October 2016

1 reference

0 references

1 reference